Free Newsletter
Once-daily pill rebuilds bone in rats, mice
Most available osteoporosis treatments can only prevent the breakdown of old bone. But an investigational drug that effectively cured osteoporosis in mice and rats in a study could point the way to a new class of therapies, according to researchers from Columbia University Medical Center.
A little more than a year after the publication of research that found serotonin released by the gut inhibits bone formation, a team led by Gerard Karsenty read about the investigational drug LP533401, which is able to inhibit serotonin in the gut. "When we learned of this compound, we thought that it was important to test it as proof of principle that there could be novel ways to treat osteoporosis with therapies that can be taken orally and regulate the formation of serotonin," Karsenty says in a statement.
The researchers tested the compound in rodents experiencing post-menopausal osteoporosis-administering the compound to the animals once a day for up to six weeks. Results demonstrated that osteoporosis was prevented from developing, or when already present, could be fully cured, according to a statement. In addition, levels of serotonin were normal in the brain, indicating the compound was unable to cross the blood-brain barrier, thereby avoiding many potential side effects.
Study results were published in the Feb. 7 issue of Nature Medicine.
- check out the press release
- the Nature Medicine article is available for purchase here
Related Article:
Amgen's D-mab emerged from early protein research
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: